Literature DB >> 14657952

Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases.

Cord Langner1, Manfred Ratschek, Peter Rehak, Luigi Schips, Richard Zigeuner.   

Abstract

MUC1 (epithelial membrane antigen) is a membrane-associated mucin known to interfere with both cell-cell and cell-matrix adhesions. Overexpression has been associated with poor prognosis in a variety of cancers. We investigated the expression of MUC1 (using two different antibodies, MA695 and E29) and E-cadherin in renal cell carcinomas (137 conventional, 23 chromophobe, 20 papillary, and eight unclassified tumors) with respect to diagnostic and prognostic significance using a tissue microarray technique. Immunoreactivity was correlated with histological subtype, pT-stage, and grade using the chi2 test or the Fisher's exact test, respectively. Impact on disease-free survival was analyzed using the Kaplan-Meier method and the log-rank test. Immunoreactivity of more than 10% of cancer cells with MA695, E 29, and E-cadherin antibodies was found in 112/133 (84%), 86/133 (65%), and 7/131 (5%) conventional, 20/22 (91%), 19/22 (86%), and 21/22 (95%) chromophobe, 13/20 (65%), 8/20 (40%), and 3/20 (15%) papillary as well as 5/8 (63%), 5/8 (63%), and 4/8 (50%) unclassified carcinomas, respectively. The two different MUC1 antibodies yielded comparable staining results. A diffuse cytoplasmic staining pattern for MUC1 was found exclusively in chromophobe carcinomas, whereas conventional and papillary subtypes showed predominantly membranous staining (P<0.0001). Regarding papillary carcinomas, MUC1 was predominantly associated with type 1 (P=0.0001), and E-cadherin with type 2 (P=0.049) tumors. The cellular staining pattern of MUC1 in conventional tumors was related to pT-stage (P=0.002) and tumor grade (P=0.001): Low-stage (pT1/pT2) and grade (G1/G2) tumors showed a predominantly apical membranous staining, high-stage (pT3a/pT3b) and grade (G3/G4) tumors a predominantly circumferential membranous staining (with or without additional diffuse cytoplasmic immunoreactivity), which, in the conventional subtype, was associated with poor prognosis (P<0.0001). In conclusion, MUC1 and E-cadherin are diagnostically and prognostically useful markers in renal tumor pathology, especially when cellular staining patterns are considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14657952     DOI: 10.1038/modpathol.3800032

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  22 in total

1.  t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.

Authors:  Nathaniel E Smith; Peter B Illei; Mohamed Allaf; Nilda Gonzalez; Kerry Morris; Jessica Hicks; Angelo Demarzo; Victor E Reuter; Mahul B Amin; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

2.  TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Authors:  Sounak Gupta; Sarah H Johnson; George Vasmatzis; Binu Porath; Jeannette G Rustin; Priya Rao; Brian A Costello; Bradley C Leibovich; R Houston Thompson; John C Cheville; William R Sukov
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

3.  Expression of claudin-7 in benign kidney and kidney tumors.

Authors:  Lin Li; Jorge L Yao; P Anthony di Sant'Agnese; Patricia A Bourne; Maria M Picken; Andrew N Young; Steven S Shen; Jiaoti Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

4.  Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis.

Authors:  Steffen Rausch; Johanna Beermann; Marcus Scharpf; Jörg Hennenlotter; Falko Fend; Arnulf Stenzl; Daniel Schollenberger; Jens Bedke; Stephan Kruck
Journal:  World J Urol       Date:  2016-03-19       Impact factor: 4.226

5.  Effects of resveratrol on gene expression in renal cell carcinoma.

Authors:  Ting Shi; Louis S Liou; Provash Sadhukhan; Zhong-Hui Duan; Andrew C Novick; John G Hissong; Alexandru Almasan; Joseph A DiDonato
Journal:  Cancer Biol Ther       Date:  2004-09-21       Impact factor: 4.742

6.  Synergistic effects of snail and quercetin on renal cell carcinoma Caki-2 by altering AKT/mTOR/ERK1/2 signaling pathways.

Authors:  Fan-Dong Meng; Yan Li; Xin Tian; Ping Ma; Cheng-Guang Sui; Li-Ye Fu; You-Hong Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma.

Authors:  Thaer Khoury; Dongfeng Tan; Jianmin Wang; Marilyn Intengan; Jun Yang; Sadir Alrawi; Peisha Yan; James C Byrd
Journal:  BMC Clin Pathol       Date:  2006-01-12

8.  E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.

Authors:  Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther
Journal:  Biomark Res       Date:  2021-06-05

9.  Distinct Cytoplasmic Expression of KL-6 Mucin in Chromophobe Renal Cell Carcinoma: A Comparative Immunohistochemical Study with Other Renal Epithelial Cell Tumors.

Authors:  Mana Fukushima; Kayoko Higuchi; Hisashi Shimojo; Takeshi Uehara; Hiroyoshi Ota
Journal:  Acta Histochem Cytochem       Date:  2012-09-11       Impact factor: 1.938

10.  MUC1 marks collecting tubules, renal vesicles, comma- and S-shaped bodies in human developing kidney tubules, renal vesicles, comma- and s-shaped bodies in human kidney.

Authors:  D Fanni; N Iacovidou; A Locci; C Gerosa; S Nemolato; P Van Eyken; G Monga; S Mellou; G Faa; V Fanos
Journal:  Eur J Histochem       Date:  2012-10-26       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.